好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

RT001 First-in Human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich’s Ataxia
Movement Disorders
S17 - (-)
003
Authors/Disclosures
Theresa A. Zesiewicz, MD (University of South Florida)
PRESENTER
Dr. Zesiewicz has received personal compensation for serving as an employee of Medscape. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lexeo. Dr. Zesiewicz has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Steminent. Dr. Zesiewicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Larimar. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Zesiewicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care. Dr. Zesiewicz has received intellectual property interests from a discovery or technology relating to health care.
Frederic Heerinckx, PharmD (Retrotope, Inc.) No disclosure on file
No disclosure on file
Omid Omidvar, MD (Southland Neurologic Institute) No disclosure on file
Gregory R. Bonomo, MD No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file